Palifosfamide is a novel molecule for the treatment of sof tissue sarcoma.

Palosuran (ACT-058362) is a new potent and specific antagonist of the human UT receptor with an IC50 of 3.6±0.2 nM.

Pamapimod（R-1503）is a novel p38 MAP kinase inhibitor.

Pardoprunox hydrochloride is a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist, D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist and 5-HT1A receptor (pKi = 8.5) full agonist.

Parimifasor is an immunomodulator, with anti-inflammatory activity.

Pargyline is an irreversible inhibitor of monoamine oxidase (MAO; Kis = 15 and 1.8 μM for MAO-A and MAO-B, respectively).

Paulownin can highly inhibit the growth of H. pylori and exhibits strong inhibitory specificity against H. pylori related to E. coli.

Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR-α/β, and c-Kit.

PCI-27483 is a selective small molecule inhibitor of activated coagulation factor VII (FVIIa), which is in preclinical development as a novel anti-cancer agent.

PCI-34051 is a potent and specific HDAC8 inhibitor with IC50 of 10 nM.

PD 98059 is a selective inhibitor of MEK and blocker of MAPK

PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations.PD0166285 is a novel G2 checkpoint abrogator.

PD169316 is a potent and selective p38 MAP kinase inhibitor

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM.

PDM 2 is an analog of resveratrol acting as a potent and selective aryl hydrocarbon receptor (AhR) antagonist, with a Ki of 1.2 nM.

Pentamidine Dihydrochloride(MP601205 dihydrochloride) is an antimicrobial agent.

PF-04418948 is an orally active, potent, and selective EP2 receptor antagonist (IC50 = 16 nM).

OTS193320 (OTS-193320) is a potent inhibitor of protein methyltransferase SUV39H2 with IC50 of 22.2 nM.

PF-06447475 is a highly potent, selective, brain penetrant LRRK2 inhibitor with IC0 of 3 nM/11 nM for Wt LRRK2/G2019S LRRK2 respectively.

PF-06454589 is a potent and selective LRRK2 inhibitor.

PF-06840003 is an orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1),with potential immunomodulating and antineoplastic activities.

PF-5274857 is a potent and selective Smoothened (Smo) antagonist, inhibits Hedgehog (Hh) signaling with IC50 and Ki of 5.8 nM and 4.6 nM, respectively, and can penetrate the blood–brain barrier.

PF-4989216 is a potent and selective PI3K inhibitor with IC50 of 2 nM, 142 nM, 65 nM, 1 nM, and 110 nM for p110α, p110β, p110γ, p110δ, and VPS34, respectively.

PF-8380 is a potent and specofic autotaxin inhibitor with an IC50 value of 2.8 nM.

PFI-4 is a potent and selective BRPF1 bromodomain inhibitor (IC50 = 80 nM).

PHCCC is a Group I metabotropic glutamate receptor antagonist (IC50 ~ 3 μM).

Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.

BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.

SR-11237 is a selective pan retinoid X receptor (RXR) agonist with no retinoid A receptor (RAR) activity. .

PIK-293 is a PI3K inhibitor, mostly for PI3Kδ with IC50 of 0.24 μM, 500-, 100- and 50-fold less potent to PI3Kα/β/γ, respectively.